phase II clinical study Sep 13, 2022 Cardiff Oncology Launches Phase II Trial of PLK1 Inhibitor in RAS-Mutated Colon Cancer Sep 13, 2022 Relay Therapeutics' Selective FGFR2 Inhibitor Yields 'Remarkable' Responses in Bile Duct Cancer Premium Sep 11, 2022 Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients Premium Sep 11, 2022 Selective Estrogen Receptor Degraders, Modulators Show Promise in ESR1-Mutant Breast Cancer Premium Sep 10, 2022 BMS Combo Drug Opdualag Effective in Neoadjuvant NSCLC, But Maybe No Better Than Opdivo Alone Premium Sep 8, 2022 OncXerna Begins Navicixizumab Phase II Basket Trial Sep 6, 2022 Monte Rosa to Begin Phase I/II Trial of MRT-2359 in MYC-Driven Solid Cancers Sep 2, 2022 Jacobio Pharma Doses First NSCLC Patient in JAB-21822 Trial in China Sep 1, 2022 Aston Sci. to Launch Phase II US Study of Experimental Vaccine in HER2-Low Breast Cancer Patients Aug 30, 2022 Jounce Therapeutics' Vopratelimab, Pimivalimab Combo Trial in NSCLC Fails to Meet Primary Endpoint Aug 29, 2022 RedCloud Begins Phase I/IIa Trial in EGFR TKI-Resistant Lung Cancer Aug 24, 2022 MMRF Data Fuels Greater Understanding of Multiple Myeloma Drug Resistance, Mutational Landscape Premium Aug 22, 2022 IDRx Launches With Back-to-the-Future Combination Drug Development Strategy Premium Aug 22, 2022 Kronos Begins Trial of Second SYK Inhibitor in FLT3-Mutated AML Aug 22, 2022 Emtora Nets $16.9M Grant to Advance Drug for Genetic Condition That Increases Colon Cancer Risk Aug 19, 2022 Sirnaomics Launches Phase I/II Trial of RNAi Therapeutic for Facial Skin Cancer Lesions Aug 17, 2022 Tessa Therapeutics Starts Trial of CAR T-Cell Therapy, BMS's Opdivo in Classical Hodgkin Lymphoma Aug 12, 2022 AstraZeneca, Daiichi Sankyo's Enhertu Scores FDA Accelerated Approval in HER2-Mutant Lung Cancer Aug 11, 2022 Novartis' Tabrecta Nets Full FDA Approval for NSCLC With METex14 Skipping Mutations Aug 11, 2022 New Drugs Going After 'Achilles' Heel' Resistance Mutation in NSCLC Premium Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
